A retrospective study evaluated the outcomes of FLAG and another chemotherapy using clofarabine, Ara-C and G-CSF (GCLAC) in R/R AML patients, with an additional therapy using fludarabine plus Ara-C without G-SCF (FA) serving as the control group. The gene discussed is CSF3; the disease is acute myeloid leukemia.